Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00780208 · ClinicalTrials.gov registry record · NA

Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD

A NA study, sponsored by Medical University of South Carolina.

Completed
Registry status
NA
Development phase
14
Enrollment target

NCT00780208 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 14 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00780208, a NA study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effectiveness and safety of Daytrana® in the treatment of attention deficit hyperactivity disorder (ADHD) in adults who have abused stimulants in the past. Daytrana® is a stimulant medication that has been approved by the Food and Drug Administration for the treatment of ADHD in children over the age of 6 years old.

Interventions

  • DRUG Daytrana (methylphenidate patch)

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2007-04
Est. Completion 2009-02
Phase NA

What the Registry Record Tells You About NCT00780208

The ClinicalTrials.gov registry entry for NCT00780208 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Daytrana (methylphenidate patch) is the first listed.

NCT00780208 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00780208 about?

NCT00780208 is a clinical study titled "Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD". The purpose of this study is to evaluate the effectiveness and safety of Daytrana® in the treatment of attention deficit hyperactivity disorder (ADHD) in adults who have abused stimulants in the past. Daytrana® is a stimulant medication that has been approved by the Food and Drug Administration for ...

What is the current status of trial NCT00780208?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2007-04. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00780208?

The interventions under investigation include: Daytrana (methylphenidate patch) (DRUG).

Who is sponsoring clinical trial NCT00780208?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.